XML 33 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   10,012      
Beginning balance at Dec. 31, 2022 $ 170,222 $ 1 $ 985,660 $ (1,531) $ (813,908)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities 739        
Foreign currency translation adjustment (7)        
Net loss (31,672)        
Ending balance at Mar. 31, 2023 143,845        
Beginning balance (in shares) at Dec. 31, 2022   10,012      
Beginning balance at Dec. 31, 2022 170,222 $ 1 985,660 (1,531) (813,908)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities 937        
Foreign currency translation adjustment (12)        
Net loss (64,197)        
Ending balance at Jun. 30, 2023 116,228        
Beginning balance (in shares) at Dec. 31, 2022   10,012      
Beginning balance at Dec. 31, 2022 170,222 $ 1 985,660 (1,531) (813,908)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities 1,003        
Foreign currency translation adjustment (24)        
Net loss (97,612)        
Ending balance at Sep. 30, 2023 87,257        
Beginning balance (in shares) at Dec. 31, 2022   10,012      
Beginning balance at Dec. 31, 2022 170,222 $ 1 985,660 (1,531) (813,908)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 17,569   17,569    
Common stock issued upon exercise of stock options, shares (in shares)   0      
Common stock issued upon exercise of stock options 1   1    
Common stock issued under employee stock purchase plan (in shares)   82      
Common stock issued under employee stock purchase plan 488   488    
Common stock issued upon release of restricted stock units (in shares)   49      
Net unrealized gain on marketable securities 1,057     1,057  
Foreign currency translation adjustment 1     1  
Net loss $ (122,116)       (122,116)
Ending balance (in shares) at Dec. 31, 2023 10,143 10,143      
Ending balance at Dec. 31, 2023 $ 67,222 $ 1 1,003,718 (473) (936,024)
Beginning balance at Mar. 31, 2023 143,845        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities 198        
Foreign currency translation adjustment (5)        
Net loss (32,525)        
Ending balance at Jun. 30, 2023 116,228        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities 66        
Foreign currency translation adjustment (12)        
Net loss (33,415)        
Ending balance at Sep. 30, 2023 87,257        
Beginning balance at Dec. 31, 2023 67,222 $ 1 1,003,718 (473) (936,024)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities (41)        
Foreign currency translation adjustment (19)        
Net loss (27,147)        
Ending balance at Mar. 31, 2024 $ 163,681        
Beginning balance (in shares) at Dec. 31, 2023 10,143 10,143      
Beginning balance at Dec. 31, 2023 $ 67,222 $ 1 1,003,718 (473) (936,024)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities (43)        
Foreign currency translation adjustment (9)        
Net loss (57,645)        
Ending balance at Jun. 30, 2024 $ 137,400        
Beginning balance (in shares) at Dec. 31, 2023 10,143 10,143      
Beginning balance at Dec. 31, 2023 $ 67,222 $ 1 1,003,718 (473) (936,024)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities 198        
Foreign currency translation adjustment 7        
Net loss (89,996)        
Ending balance at Sep. 30, 2024 $ 108,270        
Beginning balance (in shares) at Dec. 31, 2023 10,143 10,143      
Beginning balance at Dec. 31, 2023 $ 67,222 $ 1 1,003,718 (473) (936,024)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 14,350   14,350    
Issuance of common stock, net of issuance costs of $9 (in shares)   10,573      
Stock Issued During Period, Value, New Issues $ 119,361 $ 1 119,360    
Common stock issued upon exercise of stock options, shares (in shares) 15 15      
Common stock issued upon exercise of stock options $ 146   146    
Common stock issued under employee stock purchase plan (in shares)   88      
Common stock issued under employee stock purchase plan 496   496    
Common stock issued upon release of restricted stock units (in shares)   29      
Net unrealized gain on marketable securities 105     105  
Foreign currency translation adjustment (39)     (39)  
Net loss $ (130,927)       (130,927)
Ending balance (in shares) at Dec. 31, 2024 20,848 20,848      
Ending balance at Dec. 31, 2024 $ 70,714 $ 2 $ 1,138,070 $ (407) $ (1,066,951)
Beginning balance at Mar. 31, 2024 163,681        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities (2)        
Foreign currency translation adjustment 10        
Net loss (30,498)        
Ending balance at Jun. 30, 2024 137,400        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain on marketable securities 241        
Foreign currency translation adjustment 16        
Net loss (32,351)        
Ending balance at Sep. 30, 2024 $ 108,270